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INTRODUCTION
Central neurocytoma (CN) was first described in the 1980’s 
by Hassoun et al. [1] who studied two patients with intraven-
tricular tumors using electron microscopy. CN is a benign tu-
mor of the central nervous system that is classified as a grade 
II tumor by the World Health Organization (WHO) [2,3]. A 
combination of treatments, such as surgery with adjuvant ra-
diation, can be considered for CN despite its good prognosis 
[2-4]. Because of the tumor’s rarity and its elusive nature, only 
a limited number of studies, case reports, and reviews have 
been published on CN.
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Central neurocytoma (CN) is a rare, benign brain tumor often located in the lateral ventricles. CN may 
cause obstructive hydrocephalus and manifest as signs of increased intracranial pressure. The goal of 
treatment for CN is a gross total resection (GTR), which often yields excellent prognosis with a very high 
rate of tumor control and survival. Adjuvant radiosurgery and radiotherapy may be considered to im-
prove tumor control when GTR cannot be achieved. Chemotherapy is also not considered a primary 
treatment, but has been used as a salvage therapy. The radiological features of CN are indistinguishable 
from those of other brain tumors; therefore, many histological markers, such as synaptophysin, can be 
very useful for diagnosing CNs. Furthermore, the MIB-1 Labeling Index seems to be correlated with the 
prognosis of CN. We also discuss oncogenes associated with these elusive tumors. Further studies 
may improve our ability to accurately diagnose CNs and to design the optimal treatment regimens for 
patients with CNs.
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EPIDEMIOLOGY
CN remains relatively rare, comprising about 0.1–0.5% of 
all brain tumors [5-8]. CNs are most prevalent among young 
adults, and nearly 25% of all cases involve individuals in their 
thirties [4,9]. The age of affected individuals ranges from 8 
days old to 67 years old with an overall median age of 34 years 
[6,10]. There is no correlation between gender and the inci-
dence of CN [7,9,11,12]. Some studies have indicated higher 
incidences of CNs in Korea, India, and Japan, which is possi-
bly attributed to genetic differences among racial groups that 
make certain individuals more prone to CNs than others 
[8,10,13-28]. The higher incidence in these Asian countries, 
make this tumor an important consideration when dealing 
with intraventricular tumors in these populations.
TUMOR LOCATION
CNs are neurocytomas located within the ventricles. Most 
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CNs are found in the anterior half of the lateral ventricle, al-
though some have reported to be found in the third and fourth 
ventricles [29-31]. The tumor is also usually attached to the 
septum pellucidum near the foramen of Monroe [32,33]. The 
cellular origination of CN is unclear; however, various authors 
have suggested CN may develop from neuronal cells, neuronal 
progenitor cells, neuronal stem cells, and multipotent precur-
sor cells [11,21,29,34-36].
Neurocytomas can also occur extraventricularly, along the 
spinal cord or the brain parenchyma [10]. Extraventricular 
neurocytomas (EVN) have been found in the cerebral hemi-
spheres, spinal cord, brainstem, thalamus, pons, amygdala, pi-
neal gland, retina, and cerebellum [5,10,37-50]. EVN is also 
classified as a grade II tumor [3]. However, EVN has a wider 
morphological spectrum and a higher degree of either focal or 
diffuse ganglionic differentiation than CN [6,10,38,51-53].
CLINICAL MANIFESTATIONS
CN may increase the intracranial pressure by obstructing the 
interventricular foramen, which can lead to hydrocephalus 
[32,54]. Patients may also experience nausea, vomiting, head-
ache, seizures, decreased consciousness, weakness, and memo-
ry or vision problems [4,7,30,38,54-57]. In rare cases, intraven-
tricular hemorrhage may also occur [58]. Patients with EVN 
present with similar symptoms, in addition to weakness and 
numbness in the limbs [20,42,59,60]. These symptoms are typi-
cally present for approximately 3–6 months, although the dura-
tion of symptoms can vary from a few days to many years 
[29,30,55,61]. The duration seems to be mostly related to tumor 
location, and does not seem to be correlated to the aggressive-
ness of the tumor [4].
RADIOLOGICAL FEATURES
CN can appear as a dense mass in computerized tomogra-
phy (CT) scans indicating calcifications, which occur in up to 
50% of all cases, and present a patchy and coarse appearances 
(Fig. 1) [7,30,33]. The tumor can also be heterogeneous be-
cause of the hypodense areas related to cystic degeneration 
[4,31]. In contrast-enhanced CT scans, CNs have mild to mod-
erate enhancements [32,62]. Furthermore, CNs appear slight-
ly hypo-intense to iso-intense on T1-weighted magnetic reso-
nance imaging (MRI) (Fig. 2), and iso-intense to hyper-intense 
on T2-weighted MRI (Fig. 3) [4,29,31,32,58]. In both T1- and 
T2-weighted MRI, hypointensity can indicate the presence of 
a hemorrhage, cyst, or calcification [31]. Typically, after a con-
trast agent is injected, moderate enhancement is seen on MRI 
for CN (Fig. 4) [29,58,63]. Unfortunately, there is no estab-
lished criterion to distinguish between CN and other tumors 
such as oligodendrogliomas on CT scans and MRI [4,11,64].
SURGERY
Surgical management with a gross-total resection (GTR) is 
currently the gold standard treatment for CNs, which often 
has excellent prognosis and minimizes the chances of CN re-
Fig. 1. Axial CT demonstrating a large hypodense central neuro-
cytoma. Moderate, heterogenous hyperdensities are consistent 
with calcifications.
Fig. 2. Axial T1-weighted MRI showing a large isointense CN in 
the lateral ventricles consistent with CN. CN, central neurocytoma. 
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currence [65]. GTR is achieved in nearly 30–50% of all CN pa-
tients. In an analysis of 310 patients with CN who underwent 
a GTR, there was a 99% five-year survival rate [14,54,65,66]. 
In comparison, individuals who had surgery with only subto-
tal resection (STR) had an 86% five-year survival rate. STR of 
CN increases the rate of recurrence and decreases the rate of 
survival [65]. A recent multi-center study found that in 71 pa-
tients with CN, those with STR had a 3.8-fold higher risk of 
recurrence and adverse outcomes compared to patients with 
GTR [12]. For patients with STR, adjuvant radiotherapy was 
administered in this study.
RADIOTHERAPY
Fractionated radiotherapy
Radiotherapy and radiosurgery are non-invasive adjuvant 
treatments, but the toxicities from radiation are still being 
weighed against the benefits of tumor control [65,67]. Because 
CNs usually have excellent prognosis when GTR is achieved, 
radiation is not always indicated [25,54,55]. Radiotherapy and 
radiosurgery have been adopted as an adjuvant treatment 
when GTR cannot be achieved, the patient is inoperable, or 
the tumor is aggressive [12,61].
A recent report suggests that fractionated radiotherapy 
(FRT) after STR had a statistically significant higher tumor 
control rate and improved survival in adults [11,68]. A high-
er 5-year progression free survival has also been shown for 
patients who received adjuvant FRT after STR (67%) than 
patients without FRT (53%) [69].
Stereotactic radiosurgery 
While FRT delivers multiple fractions of radiation in lower 
dosage, stereotactic radiosurgery (SRS) administers one higher 
dose (9 to 25 Gy) of radiation in 1-5 fractions. The first litera-
ture on the use of SRS for CN was published by Schild et al. 
[54]. SRS has been suggested to be potentially favorable to 
FRT. Although not statistically significant, Patel et al. [11] 
also reported that adjuvant SRS for patients with STRs dem-
onstrated a 100% tumor control rate compared to an 87% tu-
mor control rate for patients with adjuvant FRT [54].
Garcia et al. [70] also reported a higher tumor control rate of 
93% with SRS versus 88% with FRT. The relative risk (RR) of 
SRS to FRT for recurrence was 0.57 less (95% CI: 0.21–1.57; 
log-rank p=0.85), and the RR for mortality was 0.23 less (95% 
CI: 0.05–1.05; log-rank p=0.22), although statistically insignifi-
cant. Lower complication was noted for patients with SRS, al-
though distant tumor recurrence was slightly higher in patients 
who received SRS than those who received FRT. SRS is suggest-
ed to be at least as effective as FRT in achieving tumor control.
Prognosis
Schild et al. [54] reported a 5-year survival rate for patients 
who received FRT or SRS after surgical resection of 88%, while 
the 5-year survival rate for patients without adjuvant radiation 
was only 71%. Imber et al. [69] also found significantly im-
proved survival rates when adjuvant radiotherapy is adminis-
tered following STR. Patients with STR and FRT had a 67% 
5-year survival rate, while patients with STR only had a 53% 
survival rate. Additionally, Kim et al. [71] reported that pa-
Fig. 4. Axial T1-weighted MRI with contrast showing a large isoin-
tense central neurocytoma with moderate enhancement.
Fig. 3. Axial T2-weighted MRI showing a heterogenous, hyperin-
tense central neurocytoma.
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tients with STR had a lower recurrence rate after adjuvant 
therapy of FRT or SRS (1 of 12 patients) when compared to 
patients without adjuvant radiation (3 of 12 patients), although 
the difference was statistically insignificant. Overall, adjuvant 
therapy following incomplete resection of CNs appears to re-
sult in better tumor control.
Toxicity
Complications can arise from radiation therapy. A single in-
stitutional study found that 4 out of 7 patients who received 
FRT exhibited complications, such as white matter degrada-
tion or radiation necrosis, although FRT was effective in 
achieving local tumor control [71]. Chen et al. [72] found that 
among 60 patients treated with radiation therapy, 28 patients 
exhibited grade I neurotoxicity which resulted in short-term 
memory impairment and motor deficit. Seven patients dis-
played grade II neurotoxicity, while three patients had grade 
III neurotoxicity [72]. The associated symptoms included cog-
nitive disturbance, hemianopsia, seizure, and involuntary 
movement [72].
CHEMOTHERAPY
Although chemotherapy is not a primary treatment mo-
dality for CN, chemotherapy has been used as an adjuvant or 
salvage therapy for recurrent CNs or inoperable patients 
[11,31,73]. There are no studies using chemotherapy as a 
primary form of treatment for CN, nor a comparison of the 
efficacy between radiotherapy and chemotherapy as an adju-
vant treatment [4,11,73-75]. Only a few case reports noted 
partial tumor regression following chemotherapy, and only 
one study reported a child with a complete response using a 
combination of topotecan, carboplatin, and phosphamide in 
three cycles [4,75-78]. 
HISTOPATHOLOGICAL ANALYSIS 
AND MOLECULAR PATHOGENESIS
CN has been relatively difficult to diagnose because of its 
histopathological similarity to other brain tumors, such as oli-
godendrogliomas and ependymomas [4,11,64]. Light micros-
copy is ineffective in identifying CNs [9,79,80]. Generally, im-
munohistochemistry is performed for the diagnosis of CN 
[9,29,79].
The histology of CN can vary throughout a single specimen 
and is typically benign (Fig. 5) [10]. The tumor cells create a 
“honeycomb pattern,” and appear small and round with scant 
cytoplasm and stippled chromatin [4,10,24,31,32]. Since these 
characteristics are similar to the appearance of oligodendrogli-
omas, there is a potential opportunity for misdiagnosis [4,10, 
11,24,31,32]. Likewise, the pathological features of ependymo-
mas are similar to the perivascular rosette or straight line cell 
arrangements that are also seen in CN [10]. Therefore, multi-
ple immunohistochemical markers are helpful in differentiat-
ing CNs from other tumors.
Although less commonly used, electron microscopy can be 
another helpful tool in diagnosing patients with CNs by look-
ing for parallel arrays of microtubules with dense-core neuro-
secretory granules and clear vesicles [7,21,24,36].
Immunohistochemical markers
Synaptophysin is one of the major molecular markers for CN 
[10]. Positive staining for synaptophysin, a transmembrane gly-
coprotein present in presynaptic vesicles of neurons, is a strong 
indicator for neuronal cells and its neoplasms (Fig. 6). Synapto-
physin staining is usually found in the fibrillary and perivascu-
lar areas of CN [9,81,82].
In addition to positivity for synaptophysin, negativity for 
neuron specific enolase (NSE) and vimentin has been reported 
to suggest CN over oligodendroglioma and clear cell ependy-
Fig. 5. H&E stained slide of central neurocytoma showing a pro-
liferation of small round, fairly uniform nuclei with perinuclear ha-
loes. H&E, hematoxyin eosin.
Fig. 6. Diffuse, strong cytoplasmic synaptophysin immunoexpres-
sion in central neurocytoma.
SJ Lee et al.
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moma (Table 1) [4]. NSE is a glycolytic enzyme located in the 
cytoplasm of neurons [83]. Although it is present in CN, it lacks 
neuronal specificity and has been reported to be present in 
non-neuronal neoplasms [9,24]. Vimentin is an intermediate 
filament protein found in glial cells, and is usually present in ol-
igodendrogliomas and clear cell ependymomas, but absent in 
CN [84,85].
Epithelial membrane antigen (EMA) is another protein that 
differentiates CN from oligodendroglioma and ependymoma. 
EMA, which is normally expressed in epithelial cells, is pres-
ent in ependymal cells in the central nervous system, as well 
as in ependymomas [86]. Furthermore, EMA positivity has 
also been linked with other glial tumors such as glioblasto-
ma, astrocytoma, and oligodendroglioma [86,87]. Thus posi-
tivity of EMA can suggest ependymoma and oligodendrogli-
oma over CN [4].
Neuronal nuclei (NeuN) is present in the nuclei and peri-
nuclear cytoplasm of post-mitotic neurons in the central ner-
vous system. Positive staining for NeuN suggests the neuronal 
nature of neoplasms and is considered to be a reliable marker 
for clear cell neoplasms of the central nervous system, which 
include CN, oligodendroglioma, and clear cell ependymoma 
[4,88,89]. It has also been reported that positive staining for 
NeuN correlates with a lower proliferation index [4,90].
Glial fibrilllary acidic protein (GFAP), which is detected in 
glial cell tumors, is usually absent in CN. It is the most abun-
dant intermediate filament protein in astrocytes, and is usually 
present in astrocytes that infiltrate or surround CN [4,21,51-
53,91,92]. Cases of CN with GFAP positivity suggest glial dif-
ferentiation of bipotential (astrocytic and neuronal) precursor 
cells, and also correlates with a more malignant disease course 
[93].
Neurofilament (NF), which exists as intermediate filaments 
in neurons, is largely absent in CN. This suggests that the full 
differentiation of CN cells to developed neurons is rare 
[12,34]. Vasiljevic et al. [12] reported that positivity in NF is a 
key diagnostic difference between CN and pineal parenchy-
mal tumor.
Oligodendrocyte transcription factor 2 (Olig2), which is a 
transcription factor that regulates oligodendroglial differen-
tiation, is also generally absent in CN. Olig2 can be used as a 
diagnostic marker for oligodendroglioma, and positivity for 
Olig2 suggests oligodendroglioma over CN [94,95]. This also 
argues the rarity of CN cells undergoing glial differentiation.
Chromagranin A (chrA) is a neuroendocrine protein locat-
ed on secretory vesicles of neurons. ChrA is generally absent 
in CN, but cases of positivity have been reported [96-98]. Peng 
et al. [96] suggested that the positivity of chromogranin A may 
be due to the presence of ganglion cells in CN. Overall, ChrA 
is not a reliable marker for the diagnosis of CNs; however, 
ChrA positivity in some CNs may provide an insight to the 
cellular and developmental origins of CN [98].
Pathology (Ki-67)
The MIB-1 Labeling Index (MIB-1 LI) is an important 
prognostic tool for CN (Fig. 7). In 2015, Imber et al. [69] mea-
sured progression-free survival (PFS) by Kaplan-Meier and 
Cox proportional hazards methods, and found that the two 
Table 1. IHC markers for CN compared to oligodendroglioma and ependymoma
IHC marker Neurocytoma Oligodendroglioma Ependymoma
Synaptophysin + - -
NSE - - -
Vimentin - + +
EMA - + +
NeuN + + +
GFAP - + +
NF - - -
Olig2 - + -
IHC, immunohistochemistry; CN, central neurocytoma; NSE, neuron specific enolase; EMA, epithelial membrane antigen; NeuN, neuronal 
nuclei; GFAP, glial fibrilllary acidic protein; NF, neurofilament; Olig2, oligodendrocyte transcription factor 2
Fig. 7. Ki-67 stain showing a low proliferation index in central 
neurocytoma.
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year PFS was 48% for MIB-1 LI >4%, and 90% for MIB-1 LI 
<4%. Similarly, CN with MIB-1 LI <2% had a 10-year sur-
vival rate of 90%, compared to MIB-1 LI >2%, which had a 
10-year survival rate of 63%.
MIB-1 LI has also been reported to be an indicator of tumor 
relapse. It has been reported that CN with MIB-1 LI >2% had 
a 63% chance of recurrence; whereas CN with MIB LI <2% 
had only a 22% chance of recurrence over a 150-month period 
[4,99]. Furthermore, Chen et al. [93] found that out of the nine 
patients presented in the study, the four that experienced tu-
mor recurrence or death from continuous tumor growth or 
surgical complications had MIB-1 LI >2%, suggesting that an 
MIB-1 LI >2% may indicate a more aggressive disease course.
MIB-1 LI may also be used to determine the tumor grade. 
Sharma et al. [18] reported that the only proliferation marker 
that correlated with CN atypia is the MIB-1 LI. Söylemezoglu 
et al. [52] found that a MIB-1 LI >2% correlated with micro-
vascular proliferation and suggested that a CN with MIB-1 LI 
>2% should be termed ‘atypical’ [4]. Atypical CN are also 
known to spread through the cerebrospinal fluid and metas-
tasize in the ventricles or the spinal cord [100-103].
Genetic alterations
Many types of genetic mutations have been associated with 
CNs. N-myc proto-oncogene (N-Myc), which is an oncogene 
associated with the development of other cancers such as neu-
roblastoma and medulloblastoma, is overexpressed in CN 
[34,104-106]. The overexpression of N-Myc in neuroblastoma 
seems to indicate a poorer prognosis [34,107]. N-Myc is re-
quired for neural proliferation, but inhibits complete neural 
differentiation of neuronal progenitor cells [34,108]. The levels 
of N-Myc are inversely related to the tumor suppressor gene 
encoding Myc box-dependent-interacting (BIN-1) protein, 
which has been found to be significantly underexpressed in 
neurocytomas, as well as other tumors [34,105]. This suggests 
that CN may contain a mutation somewhere in the pathway 
that includes both N-Myc and BIN-1, and that the respective 
overexpression and underexpression of N-Myc and BIN-1 
may play a large role in CN tumorigenesis [34,105].
Phosphatase and tensin homolog (PTEN) gene is a tumor 
suppressor gene also found to be overexpressed in CN [105]. 
Musatov et al. [109] showed that PTEN overexpression inhib-
its neural differentiation in PC12 cells by phosphoinositide 
3-kinase and mitogen-activated protein kinase pathways [34]. 
Thus, PTEN and N-Myc overexpression together could po-
tentially warrant the lack of full neuronal differentiation fre-
quently seen in CN.
In addition, Sim et al. [35] found that insulin-like growth 
factor 2 was overexpressed in CN cells compared to cells in 
the ventricular zone, and may play a key role in the prolifera-
tion of neurocytoma, similar to its role in the proliferation of 
glioblastoma multiforme [34,110].
Similarly, platelet-derived growth factor D (PDGF-D) and 
neureglin 2 (NRG-2) were found to be overexpressed in CN. 
PDGF-D overexpression has been found to be involved with the 
maturation of certain tumors [34,111], whereas NRG-2 overex-
pression has been linked to the proliferation of neuroblasts, as 
well as the aggressiveness in breast carcinoma [34,112,113]. 
Overall, PDGF-D and NRG-2 can also offer an explanation for 
the tumorigenesis of neuronal progenitor cells [34].
CONCLUSION
CN is a benign tumor of the CNS that has an excellent prog-
nosis. Surgery with gross total resection is the most preferable, 
correlated with the best long-term survival rates and local tu-
mor control. Adjuvant radiotherapy may be considered for re-
sidual CN following STR, large CN size, or CNs near inopera-
ble regions. Radiotherapy or chemotherapy the primary trea-
tment for CNs has not been thoroughly examined.
Many histological markers are available for the diagnosis of 
CN, although some markers are also sensitive to other tumors. 
The MIB-1 LI is currently the most accurate tool to determine 
prognosis, tumor relapse, and tumor grade. Further molecular 
and genetic studies may offer insights into other immunohis-
tochemical methods for improved diagnostic accuracy.
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